To prepare an EIC Accelerator application for the APC148-project; A clinical phase 1 study with a novel beta-lactamase inhibitor

Antimicrobial resistance (AMR) is an emerging and devastating global health problem caused directly by use and over-use of antibiotics. AMR jeopardizes our ability to perform many life-saving procedures such as surgery, cancer treatment, transplantations, etc. This project addresses this global need by developing novel technology securing antibiotic sensitivity in life-threatening, potentially multi-drug resistant bacterial infections. Bacteria defend themselves by producing enzymes that destroy antibiotics. APC148 is a novel enzyme-inhibitor that destroys these enzymes and restores bacteria sensitivity to antibiotics. APC148 efficacy and safety has been documented through preclinical studies and is ready for the first test in humans (phase 1). In this project we will test the safety of APC148 in healthy voluntees to establish a safe dose for further investigationns in combination with antibiotics.